MARKET

ONC

ONC

BeOne Medicines Ltd.
NASDAQ
275.34
-1.78
-0.64%
After Hours: 275.34 0 0.00% 17:39 06/25 EDT
OPEN
277.71
PREV CLOSE
277.12
HIGH
280.96
LOW
274.29
VOLUME
231.75K
TURNOVER
--
52 WEEK HIGH
385.22
52 WEEK LOW
239.25
MARKET CAP
30.21B
P/E (TTM)
61.64
1D
5D
1M
3M
1Y
5Y
1D
BeOne Medicines’ Real‑World Lung Cancer Study Puts Tislelizumab Under the Market Microscope
TipRanks · 10h ago
BeOne Medicines (ONC) Deepens Cancer Ties With Blood Cancer United And New Hematology Data: What Changes?
Simply Wall St · 16h ago
Kymera Appoints Felix Baker As Board Chairman, Succeeds Bruce Booth
NASDAQ · 19h ago
BeOne Medicines (ONC) Stock Could Be 34% Undervalued on Its Oncology Growth Narrative
Simply Wall St · 2d ago
Weekly Report: what happened at ONC last week (0615-0619)?
Weekly Report · 3d ago
BeOne Medicines Executives Quietly Cash In on a Wave of Insider Stock Sales
TipRanks · 06/19 02:06
BeOne Medicines (ONC) Investors Track New Data from BeiGene’s Chronic Urticaria Trial
TipRanks · 06/18 16:32
BeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors
TipRanks · 06/18 16:32
More
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Webull offers BeOne Medicines AG (ADR) stock information, including NASDAQ: ONC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONC stock methods without spending real money on the virtual paper trading platform.